Form D · Biotechnology
MimiVax, LLC
Buffalo, NY · CIK 0001634552
Offering snapshot reported Aug 12, 2019 · SEC filing
- Reported sold
- Yet to sell Offering amount: $10M
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 12, 2019 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Feb 23, 2015 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0 (estimated)
- Finders' fees
- $0 (estimated)
- Form D file number
- 021-346322
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| N/A | None |
Source: Form D, filed Aug 12, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Ciesielski | Executive |
| Robert Fenstermaker | Executive |
| Scott Friedman | Executive |
| Jeremy Jacobs, Jr. | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Elms & Carlton Streets Mrc 105
Buffalo, NY, 14263
Buffalo, NY, 14263